Promoter hypermethylation of the phosphatase DUSP22 mediates PKA-dependent TAU phosphorylation and CREB activation in Alzheimer's disease

Hippocampus

Volumn 24, Issue 4, 2014, Pages 363-368

  Sanchez Mut, Jose Vicente ^a,b   Aso, Ester ^b   Heyn, Holger ^a   Matsuda, Tadashi ^c   Bock, Christoph ^d   Ferrer, Isidre ^b   Esteller, Manel ^a,b,e  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOKKAIDO UNIVERSITY   (Japan)

^d ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^e INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Brain and neurodegeneration; DNA methylation; Epigenetics; Hippocampus

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DUAL SPECIFICITY PHOSPHATASE 22; PHOSPHATASE; TAU PROTEIN; UNCLASSIFIED DRUG; CREB1 PROTEIN, HUMAN; DUAL SPECIFICITY PHOSPHATASE; DUSP22 PROTEIN, HUMAN; MAPT PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DNA METHYLATION; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; AGED; FEMALE; GENE EXPRESSION; GENETIC EPIGENESIS; GENETICS; HIPPOCAMPUS; MALE; METABOLISM; METHYLATION; PHOSPHORYLATION; PHYSIOLOGY; PROMOTER REGION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CELL LINE, TUMOR; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DUAL-SPECIFICITY PHOSPHATASES; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION; HIPPOCAMPUS; HUMANS; MALE; METHYLATION; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 84904242129     PISSN: 10509631     EISSN: 10981063     Source Type: Journal    
DOI: 10.1002/hipo.22245     Document Type: Article

References (27)

1. Andersson M, Konradi C, Cenci MA. 2001. cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum. J Neurosci 21:9930-9943.
2. Bakulski KM, Dolinoy DC, Sartor MA, Paulson HL, Konen JR, Lieberman AP, Albin RL, Hu H, Rozek LS. 2012. Genome-wide DNA methylation differences between late-onset Alzheimer's disease and cognitively normal controls in human frontal cortex. J Alzheimers Dis 29:571-588.
3. Bertram L, Tanzi RE. 2008. Thirty years of Alzheimer's disease genetics: The implications of systematic meta-analyses. Nat Rev Neurosci 9:768-778.
4. Bibikova M, Le J, Barnes B, Saedinia-Melnyk S, Zhou L, Shen R, Gunderson KL. 2009 Genome-wide DNA methylation profiling using Infinium® assay. Epigenomics 1:177-200.
5. Chen AJ, Zhou G, Juan T, Colicos SM, Cannon JP, Cabriera-Hansen M, Meyer CF, Jurecic R, Copeland NG, Gilbert DJ, Jenkins NA, Fletcher F, Tan TH, Belmont JW. 2002. The dual specificity JKAP specifically activates the c-Jun N-terminal kinase pathway. J Biol Chem 277:36592-36601.
6. Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD. 2001. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 21:4125-4133.
7. España J, Valero J, Miñano-Molina AJ, Masgrau R, Martín E, Guardia-Laguarta C, Lleó A, Giménez-Llort L, Rodríguez-Alvarez J, Saura CA. 2010. beta-Amyloid disrupts activity-dependent gene transcription required for memory through the CREB coactivator CRTC1. J Neurosci 30:9402-9410.
8. Hawrylycz MJ, Lein ES, Guillozet-Bongaarts AL, Shen EH, Ng L, Miller JA, van de Lagemaat LN, Smith KA, Ebbert A, Riley ZL, Abajian C, Beckmann CF, Bernard A, Bertagnolli D, Boe AF, Cartagena PM, Chakravarty MM, Chapin M, Chong J, Dalley RA, Daly BD, Dang C, Datta S, Dee N, Dolbeare TA, Faber V, Feng D, Fowler DR, Goldy J, Gregor BW, Haradon Z, Haynor DR, Hohmann JG, Horvath S, Howard RE, Jeromin A, Jochim JM, Kinnunen M, Lau C, Lazarz ET, Lee C, Lemon TA, Li L, Li Y, Morris JA, Overly CC, Parker PD, Parry SE, Reding M, Royall JJ, Schulkin J, Sequeira PA, Slaughterbeck CR, Smith SC, Sodt AJ, Sunkin SM, Swanson BE, Vawter MP, Williams D, Wohnoutka P, Zielke HR, Geschwind DH, Hof PR, Smith SM, Koch C, Grant SG, Jones AR. 2012. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature 489:391-399.
9. Johannessen M, Delghandi MP, Moens U 2004. What turns CREB on? Cell Signal 16:1211-1227.
10. Lonze BE, Riccio A, Cohen S, Ginty DD. 2002. Apoptosis, axonal growth defects, and degeneration of peripheral neurons in mice lacking CREB. Neuron 34:371-385.
11. Luna-Muñoz J, Chávez-Macías L, García-Sierra F, Mena R. 2007. Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer's disease. J Alzheimers Dis 12:365-375.
12. Patterson KI, Brummer T, O'Brien PM, Daly RJ. 2009. Dual-specificity phosphatases: Critical regulators with diverse cellular targets. Biochem J 418:475-489.
13. Portela A, Esteller M. 2010. Epigenetic modifications and human disease. Nat Biotechnol 28:1057-1068.
14. Petrij F, Giles RH, Dauwerse HG, Saris JJ, Hennekam RC, Masuno M, Tommerup N, van Ommen GJ, Goodman RH, Peters DJ, Breuning MH. 1995. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 376:348-351.
15. Pugazhenthi S, Wang M, Pham S, Sze CI, Eckman CB. 2011. Downregulation of CREB expression in Alzheimer's brain and in Aβ-treated rat hippocampal neurons. Mol Neurodegener 6:60.
16. Querfurth HW, LaFerla FM. 2010. Alzheimer's disease. N Engl J Med 362:329-344.
17. Rao JS, Keleshian VL, Klein S, Rapoport SI. 2012. Epigenetic modifications in frontal cortex from Alzheimer's disease and bipolar disorder patients. Transl Psychiatry 2:e132.
18. Rubio A, Sánchez-Mut JV, García E, Velasquez ZD, Oliver J, Esteller M, Avila J. 2012. Epigenetic control of somatostatin and cortistatin expression by β amyloid peptide. J Neurosci Res 90:13-20.
19. Rudolph D, Tafuri A, Gass P, Hämmerling GJ, Arnold B, Schütz G. 1998. Impaired fetal T cell development and perinatal lethality in mice lacking the cAMP response element binding protein. Proc Natl Acad Sci USA 95:4481-4486.
20. Saura CA, Valero J. 2011. The role of CREB signaling in Alzheimer's disease and other cognitive disorders. Rev Neurosci 22:153-169.
21. Siegmund KD, Connor CM, Campan M, Long TI, Weisenberger DJ, Biniszkiewicz D, Jaenisch R, Laird PW, Akbarian S. 2007. DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PLoS One 2:e895.
22. Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H, Wanker EE, Bates GP, Housman DE, Thompson LM. 2000. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci USA 97:6763-6768.
23. Taylor SS, Ilouz R, Zhang P, Kornev AP. 2012. Assembly of allosteric macromolecular switches: Lessons from PKA. Nat Rev Mol Cell Biol 13:646-658.
24. Trivier E, De Cesare D, Jacquot S, Pannetier S, Zackai E, Young I, Mandel JL, Sassone-Corsi P, Hanauer A. 1996. Mutations in the kinase Rsk-2 associated with Coffin-Lowry syndrome. Nature 384:567-570.
25. Vitolo OV, Sant'Angelo A, Costanzo V, Battaglia F, Arancio O, Shelanski M. 2002. Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: Reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci USA 99:13217-13221.
26. Wang JZ, Xia YY, Grundke-Iqbal I, Iqbal K. 2013. Abnormal hyperphosphorylation of tau: Sites, regulation, and molecular mechanism of neurofibrillary degeneration. J Alzheimers Dis 33:S123-S139.
27. Yamamoto-Sasaki M, Ozawa H, Saito T, Rösler M, Riederer P. 1999. Impaired phosphorylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimer type. Brain Res 824:300-303.